HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33

Benzinga Newsdesk www.benzinga.com Neutral 50.9%

Neg 0% Neu 50.9% Pos 0%

HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $37 to $33.